214 related articles for article (PubMed ID: 27035536)
1. Response to Zhang and Ho: Addressing Ketamine's Use in Depression.
Newport DJ; Nemeroff CB
Am J Psychiatry; 2016 Apr; 173(4):431-2. PubMed ID: 27035536
[No Abstract] [Full Text] [Related]
2. Critical Appraisal of Existing Ketamine Trials: Existing Limitations and Limited Applicability for Treatment.
Zhang MW; Ho R
Am J Psychiatry; 2016 Apr; 173(4):431. PubMed ID: 27035535
[No Abstract] [Full Text] [Related]
3. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
Blier P
Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
[No Abstract] [Full Text] [Related]
4. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
5. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
6. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
7. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
8. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
9. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
[TBL] [Abstract][Full Text] [Related]
11. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
13. The rapid-onset antidepressant effect of ketamine: More surprises?
Raffa RB; Pergolizzi JV; Taylor R;
J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
[TBL] [Abstract][Full Text] [Related]
14. Ketamine followed by memantine for the treatment of major depression.
Kollmar R; Markovic K; Thürauf N; Schmitt H; Kornhuber J
Aust N Z J Psychiatry; 2008 Feb; 42(2):170. PubMed ID: 18197514
[No Abstract] [Full Text] [Related]
15. Ketamine for treatment-resistant depression: ready or not for clinical use?
Rush AJ
Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
[No Abstract] [Full Text] [Related]
16. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
Krystal JH
Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611
[No Abstract] [Full Text] [Related]
17. Blocking NMDA receptor at rest: a possible alleviation of depression.
Lu W
Acta Pharmacol Sin; 2011 Sep; 32(9):1087-8. PubMed ID: 21804573
[No Abstract] [Full Text] [Related]
18. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report.
Gálvez V; O'Keefe E; Cotiga L; Leyden J; Harper S; Glue P; Mitchell PB; Somogyi AA; DeLory A; Loo CK
Biol Psychiatry; 2014 Aug; 76(3):e1-2. PubMed ID: 24507509
[No Abstract] [Full Text] [Related]
19. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
[TBL] [Abstract][Full Text] [Related]
20. Ketamine and the potential role for rapid-acting antidepressant medications.
Krystal JH
Swiss Med Wkly; 2007 Apr; 137(15-16):215-6. PubMed ID: 17525875
[No Abstract] [Full Text] [Related]
[Next] [New Search]
